PR Newswire Clinical TrialsOriginal article
Ribo revela datos positivos del ensayo de fase 2a de vortosiran
Phase 2positivevortosiranPositive
AI Analysis
Summary
Ribo announced positive Phase 2a trial data for vortosiran, an siRNA-based FXI inhibitor, in patients with coronary artery disease. This represents the first global clinical data on FXI inhibition via siRNA following multiple-dose administration.
Clinical Trial Data
Phase
2a
Outcome Details
Positive Phase 2a trial data for FXI inhibition via siRNA following multiple-dose administration in coronary artery disease patients
Importance:6/10
Sentiment:
0.75
Phase_2_DataPositive_ResultssiRNAFXI_InhibitionCoronary_Artery_Disease
Read the original article
Published by PR Newswire Clinical Trials on July 22, 2026 2:11 PM